Best BPC-157 providers: 7 clinic offers compared

By Peptide Care Index

The best BPC-157 providers are the ones that put three things in writing before the relevant payment: the complete price, the pharmacy that fills your order, and what you get back if you're turned down. The records we reviewed do not establish a clinical winner or confirm a supply route for your order.

We compared seven U.S. clinic and telehealth-service offers—online and in person—using their published terms, official records, and the sources linked below. Rx Peps Direct lists $134 for one injection order and $129 for a 30-capsule order, including its stated review and shipping charges. Perfect B's article lists $1,845 for six one-month cycles. Those numbers buy very different things. Our review did not establish the pharmacy and complete supply basis for your order with any of the seven. Rx order prices; Perfect B cycle prices.

Sources checked October 15, 2026. Prices are provider-published, not personal quotes; the individual source dates and limits are shown below.

One thing first: this page compares clinic and telehealth services advertising prescription care. A website selling "research use only" vials or BPC-157 supplements is not, by that sale alone, a medical provider. We explain the difference below.

Best BPC-157 providers compared: seven offers side by side

Seven U.S. clinic and telehealth services published a BPC-157 offer with a price we could check on October 15, 2026. Two are the online services grouped below; five are local clinics, including Florida Surgery & Weight Loss Center, which also advertises statewide telehealth. Their prices cover different things—one order, a 4-week fill, a "cycle," a month, a program—so the lowest number on the page is not automatically the better deal.

Table 1. BPC-157 clinic offers, as each provider publishes them. U.S. dollars. Listed alphabetically, not ranked. Checked October 15, 2026. A published offer is not proof that a product can be supplied to you.

How to read this table. "From" means a starting price. A blank or "not stated" is unknown—not $0. An order, a 4-week fill, a calendar month, a "cycle," and a two-month program are different units, so don't line them up as if they were the same purchase. A vial's milligrams describe what's in the box; they aren't a dose or a duration. The reviewed offers do not consistently identify the BPC-157 salt or full formulation; ask for those details before treating similarly named products as equivalent.

Requirement-by-requirement check

A finding below belongs to one specific requirement, not to the whole clinic. One clear price doesn't make every other claim on that page clear. These labels come from our Peptide Care Access Check:

• Supported — the source supports the stated criterion; a published advertisement supports what is advertised, not independent fulfillment or clinical quality.
• Contradicted — the record shows it isn't met.
• Unresolved — the pages we read don't settle it.
• Conflicting — relevant source statements disagree, and the disagreement affects that criterion.
• Not applicable — the evidence can't answer that requirement either way.

Table 2. What each provider publicly documents, checked October 15, 2026. Alphabetical. Provider-published statements, not independent verification.

How we checked the columns. We read the linked offer, price, and policy pages; matched each name to its stated role; added only the specified charges; compared denial and charge-timing language; and opened the linked laboratory report. A named author or reviewer is not proof of who will treat you, and we did not independently check anyone's license.

The next question—and what would change a finding. For the clinician and pharmacy columns, ask who is assigned to your order; assignment and relevant state records would resolve that gap. For the bill and refund columns, request a dated, itemized quote and the policies of each payee; revised terms could change those findings. For service area, ask whether the exact service and pharmacy can serve your state. For testing, request the actual report and a documented lot match; a purity claim alone cannot resolve it. This follows the Peptide Care Access Check: requirement → evidence → check → finding → next question → revision condition.

Two findings apply to all seven offers equally:

• BPC-157 appears on the final 503A Bulks List: Contradicted. It is absent from 21 CFR 216.23(a), checked October 15, 2026, in the displayed version current through October 13. That list is one ingredient pathway, not a list of every substance that can ever be compounded; FDA explains the separate ingredient conditions and interim policy.
• A complete supply basis for your exact product and pharmacy is established by this review: Unresolved. These services advertise BPC-157; we did not verify a patient-specific preparation and dispensing arrangement. That is the same unanswered question for all seven, not a mark against one of them. Ask each clinic what it relies on.

Why these seven, and why alphabetical

We included seven U.S. clinic and telehealth-service examples with a BPC-157 prescription-care advertisement and a price we could cite from their own pages on October 15, 2026. That's a selected comparison, not every clinic in the country. They're in alphabetical order because the order isn't a ranking. No clinic paid to be included, and none is a partner—see how we make money. A clinic missing from this table isn't a bad clinic; it can simply fall outside this selected review. Specific excluded examples are discussed below.

Our verdict: which BPC-157 provider is best for you?

The records we reviewed do not establish a best provider for treatment results: none supplies a head-to-head comparison of these clinics' products. What you can fairly judge here is the published service: who itemizes the price, who identifies the people and pharmacy involved, who explains refunds, and who advertises care where you live. On those specific dimensions, different offers deserve a closer look.

Table 3. Best fit by what matters to you. Editorial conclusions from public documents, checked October 15, 2026. Not a clinical recommendation.

Our overall verdict. For the two online services compared here, Pepti is the clearer bundled-price example, while Rx Peps Direct is the clearer separate-payments example and provides an inspectable sample report. These are documentation findings, not treatment rankings. Several clinics name clinicians, authors, or reviewers, but those roles do not tell you who will handle your visit. Our review did not establish your assigned pharmacy and the complete basis for supplying your preparation through any of the seven. Get those two answers in writing before committing to the product.

What this verdict can't tell you. We read public pages. We didn't buy anything, call any clinic, check licenses, or test products. A written quote for your order is what counts, and it can differ from the website.

Once you've picked a front-runner, the job is no longer comparing names—it's getting the missing answers for that one offer. Peptide Care Index's Find My Peptide Path tool lays out the BPC-157 access evidence, the provider checks, and the fee questions in one place, so you can send the clinic exactly what's still blank. It's free, with no account or email.

Find My Peptide Path

What each BPC-157 provider costs, start to finish

Rx Peps Direct's disclosed order charges add up to $134 for one specified vial or $129 for 30 capsules; neither is a confirmed personal bill or a measure of equivalent treatment. The longest stated single-peptide plans in this comparison run six months: Moonshot lists $1,200, while Perfect B's article lists $1,845 for six one-month cycles. What you pay today can be smaller than what you commit to. Compare three things for each offer: the amount due now, the total for the first period, and what repeats.

Table 4. Payment timing and what repeats. U.S. dollars, provider-published, checked October 15, 2026. Our arithmetic in brackets.

Four worked examples that change the math

1. A 4-week bill can land twice in one month (hypothetical). Pepti's billing terms describe a 28-day/supply-cycle renewal, not necessarily once each calendar month. If an unchanged $209 fill were charged on October 1 and again on October 29, you'd pay $418 in October. That's billing arithmetic, not a prediction of your schedule.

2. A "monthly" average isn't a monthly bill. Moonshot lists $635 for 3 months. Three single months at $250 would be $750, so the 3-month plan costs $115 less—the same savings the clinic advertises. But $211.67 a month is only an average. If the $635 is due up front, that's what leaves your account on day one. The same logic applies to its 6-month plan: $1,200 versus $1,500 for six single months, a $300 difference. These are our calculations from the published plan prices, not confirmation of its payment schedule.

3. A deposit is part of the price, not on top of it. Perfect B says its $150 consultation deposit is credited toward treatment. If that credit applies to your first cycle, the cycle still costs $445: $150 up front and $295 later. Adding the deposit again would wrongly turn it into $595. Its multi-cycle plans cost less per cycle—$1,135 for 3 cycles versus $1,335 for three single cycles, and $1,845 for 6 versus $2,670—but agreeing to one means a bigger total commitment. These are our calculations from the article's cycle prices; confirm the current plan and when each payment is due.

4. Per-order pricing repeats the review fee (hypothetical). Rx Peps Direct charges $39 for every order. Three separate single-vial orders at the stated prices would be 3 × $134 = $402. We aren't saying how long a vial lasts; that's between you and the prescriber. This hypothetical uses the published order charges and per-order review terms, without assuming extra patient-specific services cost nothing.

Is the cheapest BPC-157 provider worse?

Price alone does not establish product quality or treatment results. A higher price can buy real things—an in-person exam, scheduled follow-up, lab monitoring—but only if those things are actually named in the offer. An unexplained premium is just a higher price. And a low price isn't proof of a bad product. Compare the written terms, not the headline number.

For capsule prices, retail bottles, research-item prices, and a fill-in-the-blanks quote worksheet, see our BPC-157 cost guide and peptide price list.

What happens if you're turned down or the pharmacy can't fill it?

Being turned down and having an order go unfilled are different situations, and different businesses may hold your money in each. In this review, Rx Peps Direct and Pepti provided the denial/refund policies summarized below. We did not establish equivalent no-prescription terms for the other five from the pages reviewed; that does not mean no such policy exists.

Table 5. Published refund and cancellation terms. Checked October 15, 2026. Provider-published policies, not legal advice about a specific dispute.

A wording conflict to ask about. Pepti's price page says unapproved medication is not charged. Its refund policy says payment is collected first and refunded within 5–10 business days if the clinician declines. Both describe no net medication cost after denial, but they describe different things happening to your card. We label the charge timing Conflicting, not the existence of a published denial-refund promise. Ask whether checkout is a hold or an actual charge and when any refund period starts; business days are not calendar days.

Pay for the visit and the product as two separate decisions

A consultation can be worth paying for even if no prescription follows—as long as you know what the fee buys. A product payment needs clearer answers: the exact product, the pharmacy, and the refund rules. If a clinic can't explain the pharmacy or supply basis yet, that isn't proof of a scam. It's a reason to hold the product payment until the answer is in writing. Pay for an evaluation only if you understand its fee and would value the visit without a BPC-157 prescription.

You may not need a new provider at all. If you already see a clinician for the problem you're hoping to treat, you can bring this question to them.

Online or in-person BPC-157 providers?

The online examples have lower disclosed order prices than the local clinic-start examples whose consultation and product charges can be added, but they are not equivalent purchases. Local clinics offer a place to be seen; some also use telehealth. The visit format alone does not establish product quality, treatment benefit, or whether the particular service meets your clinical needs.

Table 6. Online vs. in-person offers in this comparison. Checked October 15, 2026.

Ask an online provider whether a video visit ever happens, or whether review is by questionnaire only. Ask an in-person clinic whether the product is shipped to you from a separate pharmacy—several of these clinics have you inject at home.

Is BPC-157 legal to get from a provider now?

A specific offer's supply basis is not settled by a prescription or a headline. ABC News and Time reported an 8–6 vote, with one abstention, recommending BPC-157 for the 503A Bulks List on July 23, 2026. FDA describes that committee's advice as non-binding. The final list we checked, displayed current through October 13, still does not include BPC-157. Our focused FDA and Federal Register check on October 15 did not identify a proposed or final rule adding it.

A few terms, defined once:

• Compounding means combining, mixing, or changing ingredients to make a medicine for a patient's needs. It can occur in more than one compounding framework; compounded finished drugs are not FDA-approved.
• 503A pharmacy is shorthand here for a pharmacy operating under section 503A's compounding conditions, generally for individually identified patients. A state license alone does not show that a particular preparation meets those conditions. FDA's 503A explanation.
• The 503A Bulks List is the final list of bulk ingredients for the pathway used when no applicable USP or NF monograph—an official ingredient standard—exists and the substance is not a component of an approved drug. FDA's May 11, 2026 staff evaluation identifies neither a relevant monograph nor an approved-drug component for BPC-157 free base or acetate (page 9). FDA also describes a separate interim policy; none of these is finished-product approval.

BPC-157 FDA status timeline

Table 7. Dated FDA records and actions on BPC-157.

What the vote did—and didn't—change

The reported vote recommended a different outcome from the FDA staff assessment; it did not itself change the rule. FDA says it addresses these substances through notice-and-comment rulemaking. A proposed addition, comments on that proposal, and an effective final addition are different stages. The records inspected here do not provide a confirmed BPC-157 rulemaking date or guarantee that FDA will add it. FDA staff had recommended against adding the evaluated forms over evidence and safety questions.

So a claim that the July advisory vote made BPC-157 "FDA approved" or authorized a particular order goes beyond that event. No FDA-approved BPC-157 medicine was identified in the approval and compounding records reviewed here; the committee's advice is not a finished-drug approval or a final list addition.

So how are these clinics selling it?

The advertisements do not fully explain each clinic's supply basis, and we should not guess what legal position a clinic relies on. FDA's interim policy describes conditional enforcement discretion for Category 1 substances; withdrawal from Category 2 is not automatic Category 1 placement. BPC-157 does not appear in the Category 1 list in FDA's May 14, 2026 file. We did not verify how an applicable exception or other basis would support a particular order, and no pharmacy-law specialist reviewed these offers. Ask each clinic, in writing, what it relies on to supply this exact preparation. A license or a "503A compliant" badge answers a different question.

An offer invoking a 503B outsourcing facility needs its own check. FDA describes a separate 503B ingredient framework; registering a facility under 503B does not establish that BPC-157 meets its bulk-substance requirements.

For the full regulatory explanation, see is BPC-157 FDA approved? and our record of the FDA peptide hearing.

What would change our answer: a new applicable FDA action, an updated category record, a final-list amendment and its effective date, a finished-product approval, or documentation that resolves the exact offer's supply basis. Each would change only the finding it actually addresses; a proposed rule would not itself authorize a fill.

Why Hims & Hers and other big names aren't on this list

A familiar brand name is not evidence of a current BPC-157 offer. In its August 10, 2026 earnings call, Hims & Hers described preparations involving BPC-157 while awaiting FDA decisions and rulemaking. That is a dated business plan, not a price or patient-service commitment. Several names in older "best BPC-157" articles were included even when those articles did not document a BPC-157 offer. We did not use those lists as proof of current availability.

Table 8. Names you'll see elsewhere. Dated sources reviewed October 15, 2026; not a current inventory audit of every named business.

If you know a clinic with a public BPC-157 price and terms, send us the link.

Research peptide sellers and supplement brands aren't providers

A "research use only" sale does not establish a patient-care service. The label describes laboratory use, not a clinician evaluating you or a pharmacy dispensing treatment. A purity report does not make a vial suitable for people, and a low research-item price is not an equivalent prescription-care price.

A research-seller ranking based on price per milligram or coupon codes does not answer who will provide clinical care. We do not recommend research-use sellers as treatment suppliers. Capsules and gummies marketed as supplements are another separate category: FDA's staff evaluation notes they are being marketed, which is an observation, not an approval (page 9). For oral products, see our BPC-157 capsules guide.

How to choose among the best BPC-157 providers

Pick the provider that answers your questions in writing before you pay. Some answers should come before you pay for a visit; others—like the exact pharmacy—may only come after an evaluation, but they should come before you pay for the product. If a clinic won't answer, that isn't proof of a scam. It's a reason to wait.

The before-you-pay checklist

BPC-157 provider checklist and clinic message

Peptide Care Index · Sources checked October 15, 2026

Use this with a new clinic or one you already trust. A consultation does not guarantee a prescription, and a prescription does not establish that a pharmacy can fill the exact preparation. Missing information is not proof of fraud; it is a question to resolve before the relevant payment. You do not need to send health information to Peptide Care Index.

A message you can send to any provider

You can use this with a new clinic or one you already trust. It doesn't ask the clinic to promise a prescription, and you don't need to share health details with us to use it.

Before I pay, please confirm what this fee buys and whether it's refundable if treatment isn't prescribed. For the BPC-157 offer, please tell me the form (acetate, free base, or other), route, strength, total quantity, and any other active ingredients. Please name the clinician who would evaluate me and the pharmacy that would dispense my order, and confirm both can serve my state. What current rule or policy do you rely on to supply this exact preparation? Please itemize everything I'd pay now and later, including labs, membership, shipping, and follow-up, and tell me about any automatic renewal, minimum commitment, and cancellation deadline. If a prescription is written but the pharmacy can't fill it, which business refunds which payment, and how quickly? I understand an evaluation doesn't guarantee a prescription.

Source and scope

Original checklist and message: Peptide Care Index. Best BPC-157 providers: 7 clinic offers compared. This sheet is not a patient assessment, provider approval, or confirmation of a lawful supply route. It contains no treatment protocol or personal dosing instructions.

For the underlying distinctions, read FDA's 503A framework, compounding questions and answers, online-pharmacy checks, and state pharmacy-board directory. Pharmacy licensing and an ingredient's access basis are separate checks. These public FDA resources are not a list of BPC-157 suppliers.

Reuse the checklist and message with Peptide Care Index credited. Keep the source date and qualifications with a printed copy. No account, email, payment, or medical details are required to use this sheet.

Claim decoder: what provider phrases actually mean

For a named pharmacy, use FDA's online-pharmacy checks and state pharmacy-board directory. Those checks concern the business and professional; they do not approve the BPC-157 product or settle its supply basis.

Red flags worth pausing on

• No prescription step, or an "intake" that's just a checkout form.
• A dosing "protocol" sold before anyone reviews your health.
• Claims that BPC-157 is "FDA approved."
• Pressure to prepay several months before your first evaluation.
• Refusal to name the pharmacy before you pay for the product.
• Research vials offered "for your recovery."

You now have the questions. Work through them against the offer you saved, noting which answers are still missing. Find My Peptide Path keeps the dated BPC-157 access evidence next to the provider and fee checklists, with questions you can copy or print—so you can work through those gaps before you spend anything.

Find My Peptide Path

What a provider's lab report does—and doesn't—prove

A lab report answers only the tests it lists, for the sample it lists. It doesn't make a clinic "verified," and it doesn't prove that a later shipment matches the tested sample. It's useful, specific information—just narrower than the sales page around it.

Rx Peps Direct's offer links the BPC-157 sample report we inspected. That report (ETX-260727-0539) names Optimal Balance Pharmacy and a sample of BPC-157 3 mg/mL × 5 mL, lot LG342009607, with testing completed July 31, 2026. It reports a sterility-test pass and bacterial endotoxin below 2 EU/mL. (Endotoxins are bacterial components; EU/mL is the unit the test reports, not an amount to use.) It does not show an identity or potency test on that page. We read the provider-hosted file; we did not authenticate it with the lab. We did not establish whether the other services can supply additional reports on request.

Table 9. One lab report, requirement by requirement. Source checked October 15, 2026; the sample testing was completed July 31, 2026.

For the full worked check and the provider's payment policies, see the offer and lab-report section of our BPC-157 access guide.

Does the form of BPC-157 change which provider makes sense?

The form you're offered changes which product and evidence you need to check. Results reported for one route—like an injection into a knee joint—don't carry over to a swallowed capsule or an under-the-skin shot. Pick the provider whose offer you can describe exactly, not the one with the most forms.

For the oral evidence, see the BPC-157 capsules guide. To compare substances and routes, see the peptide comparison chart.

What the human evidence says, and why it can't rank providers

The human reports discussed here do not compare one clinic's BPC-157 product with another's. They include small, uncontrolled observations using routes different from many advertised offers. They cannot establish a provider ranking or predict your result. Limited evidence is not proof that BPC-157 cannot help, either; a benefit reported in one setting does not establish the same benefit for a different product, route, or condition.

Table 10. Two original human reports. Selected examples, not the full literature.

These two papers are not the whole human literature. FDA's staff review also describes an older meeting abstract of a small, placebo-controlled study using a rectal BPC-157 preparation for ulcerative colitis. FDA found the reported methods and data inadequate to support efficacy and safety for that use; it is not evidence for a marketed capsule or under-the-skin injection. This account comes from FDA's review, page 27, not our own reading of the original abstract.

FDA's safety page identifies possible immune reactions for certain administration routes, peptide-related impurities, and difficulties characterizing the ingredient, with limited safety information. It does not provide a reliable personal risk percentage. Animal experiments, mechanisms, and anecdotes are different evidence again; they cannot silently become proof that the offered preparation heals an injury.

Clinical trials are listed, but a listing is a lead to check—not a confirmed treatment appointment. In the four full records reviewed October 15, the University of Arkansas rotator-cuff study (NCT07803250, UAMS in Little Rock) was not yet recruiting, with an estimated start of January 1, 2027 and a last posted update of September 3, 2026. Its enrollment field says 30 estimated while its summary says 20, and its control-treatment descriptions disagree.

The Hudson Biotech hamstring study (NCT07437547) lists recruiting at a site in China, 120 estimated participants, and a February 27, 2026 update; its arm coding differs from its narrative. We did not confirm recruitment with either team. The completed U.S. gummy study (NCT07752381, Parlay Wellness/Citruslabs, 40 actual participants) and stale Mexico oral-tablet record (NCT02637284, PharmaCotherapia d.o.o./Hospital Ángeles Tijuana, 42 estimated) are not documented open-enrollment options. The gummy record was first posted August 7, 2026 after its stated November 1, 2025 completion; the tablet record's last update was December 22, 2015 and its status is unknown. None of the four inspected records has posted results.

Our BPC-157 access guide walks through these four records, their contradictory fields, and what each means for access; our BPC-157 news tracker records dated developments. Estimated enrollment is not the number treated, and no posted results does not prove no publication exists elsewhere. Use the official study contact for current recruitment, eligibility, location, costs, and possible comparison-group assignment. We did not verify a recruiting U.S. place or a BPC-157 expanded-access program for you.

Special situations

Some readers don't need a provider comparison at all, or need to check something else first.

You already have a prescription or a product

Then you're not shopping anymore—you're confirming what you have. Match the label, pharmacy, form, and quantity to what was discussed at your visit, and keep your receipt and lot number. Bring product questions to the dispensing pharmacist and care questions to your prescriber. Don't change or stop a treatment based on a comparison page. If you feel unwell after using a product, contact a clinician; urgent symptoms need urgent care.

Your own doctor might prescribe it

You do not need a new clinic just because these names exist. A clinician who already evaluates your concern can discuss the relevant evidence and established alternatives, whether or not BPC-157 is prescribed. A prescription still leaves the pharmacy and supply questions to resolve. Our BPC-157 access guide covers that conversation.

Insurance, HSA, or FSA

This review did not establish insurance coverage or spending-account eligibility for a BPC-157 product or related visit. Pepti's offer page says HSA and FSA cards are "usually accepted," but accepting a payment card does not establish whether the expense qualifies under your plan. Ask your plan administrator about the exact consultation and product, and keep itemized receipts. Our cost guide covers these payment questions in more detail.

You compete in drug-tested sport

The 2026 WADA Prohibited List, effective January 1, 2026, names BPC-157 under S0, prohibited at all times. A prescription does not, by itself, override that rule. Check with your sport's anti-doping authority before using any BPC-157 product; use the list and rules that govern your competition year.

You're looking at an overseas seller

International shipping isn't the same as a U.S. access route. FDA says importing unapproved drugs for personal use is generally not allowed, with limited case-by-case considerations—not a blanket permission for a small supply (FDA personal importation).

How we checked these providers

We read the linked offer, price, policy, and service-area material from these seven services and lined up the findings requirement by requirement, using official records for regulatory facts. We also read the original reports and full trial records identified below. This was a document review—not a medical exam, a test purchase, a pharmacy inspection, or a legal opinion.

Peptide Care Index is the independent decision and access index for peptide care—helping you understand the route, the cost, the evidence, and the next step before you pay.

What we actually checked

Records read: published BPC-157 offers and available price, policy, and service-area pages from seven services, checked October 15, 2026; FDA's staff evaluation (May 11), safety page (marked current April 22), category file (May 14), July meeting materials and April 16 Federal Register notice; 21 CFR 216.23 as displayed through October 13; the linked lab report (testing completed July 31); two original human papers; all four full trial records discussed above; and the 2026 WADA list. Relevant PDF pages were inspected.

Reporting and company plans: the 8–6 vote with one abstention is attributed to ABC News and Time. We did not locate official minutes or a voting-results document on FDA's meeting page or independently count the broadcast vote. Hims & Hers' dated plan comes from its August 10 company transcript. The older ranking articles establish what those articles said, not today's provider offers.

What we didn't do: buy products, enter a patient intake or paid checkout, contact clinics, pharmacies, laboratories or study teams, check individual licenses, confirm state-specific fills, authenticate the lab report, or get a personal quote. Our FDA/Federal Register check was focused, not an exhaustive agency-record or approval-database search. The older ulcerative-colitis abstract is described from FDA's assessment, not our reading of the original abstract.

Review and dates: this page used AI assistance in research, drafting, and source checking. No clinician, pharmacist, or regulatory specialist reviewed it. A source-check date is not the article's publication date or the date each underlying fact first became current.

How to read the findings. Every label in our tables applies to one requirement. Supported means the source shows the requirement is met. Contradicted means it shows it isn't. Unresolved means the sources don't settle it. Conflicting means statements disagree, and we show both. Not applicable means that evidence can't answer that requirement. We don't give clinics overall scores, stars, or safety badges.

Selection, order, and money. The seven examples were selected for their publicly inspectable BPC-157 offers and charges; this was not a census of providers or an independent verification of every service term. They are listed alphabetically. Provider links are unpaid citations. Read our methodology, editorial standards, and how we make money. To report a change or error, use contact and corrections—please do not send medical records or payment details.

Your next step

If one offer fits the service you need, your next step is getting its missing answers in writing—not assuming a deposit secures BPC-157. If none fits, waiting for clearer access evidence is a reasonable choice. And if you already see a clinician you trust, start there.

Bring the exact offer—the clinic, the product, and the price—not just the name "BPC-157." Find My Peptide Path lays out the dated BPC-157 access evidence, the provider checks, and the fee questions to copy or print for the clinic. It's free, with no account or email. It won't prescribe anything or pick a provider for you; it helps you see what's still unanswered.

Find My Peptide Path

Sources and check dates

Linked source text was reviewed October 15, 2026. Source publication, update, and observation dates remain separate; provider documents do not confirm a patient-specific purchase or fill.

FDA and federal records

1. U.S. Food and Drug Administration. BPC-157 staff evaluation for the July 23–24, 2026 Pharmacy Compounding Advisory Committee. Dated May 11, 2026. Approval and monograph statement on page 9; proposal not to add BPC-157 in its conclusion.
2. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Content current April 22, 2026. BPC-157 row in "nominated but withdrawn."
3. U.S. Food and Drug Administration. July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting. Content current August 6, 2026.
4. Electronic Code of Federal Regulations. 21 CFR 216.23. Displayed current through October 13, 2026; checked October 15.
5. U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers.
6. U.S. Food and Drug Administration. Understanding unapproved use of approved drugs "off label".
7. U.S. Food and Drug Administration. Personal importation.

Advisory reporting, rulemaking records, and a dated company statement

8. ABC News. FDA advisory committee votes to add popular peptide BPC-157 to drug compounding list. July 23, 2026.
9. Time. An FDA committee just voted in favor of peptides. July 23, 2026.
10. U.S. Food and Drug Administration. 503A ingredient conditions, list development, and interim policy; May 14, 2026 nomination-category file; separate 503B framework.
11. Federal Register. Pharmacy Compounding Advisory Committee notice, document 2026-07361; official PDF. April 16, 2026. A meeting notice, not a final rule.
12. Hims & Hers Health. Second-quarter 2026 earnings-call transcript. August 10, 2026; peptide discussion on PDF pages 8–9 and 18. A historical company statement, not evidence of current BPC-157 pricing or FDA authorization.

Provider pages (provider-published)

13. Evolved Medical. BPC-157 peptide therapy. Offer text displayed at the October 15 check; consultation inclusion and complete vial specification not established.
14. Florida Surgery & Weight Loss Center. BPC-157 peptide therapy in Florida. Live offer read October 15, 2026; source-page modification date October 14.
15. Moonshot Medical. Peptides, medical-services consultation and pricing, and blood panels. The free initial consultation is conditioned on a diagnostic service; a separately priced test is not automatically an added BPC-157 requirement.
16. Pepti. BPC-157 cost; refund policy and subscription terms, updated August 8, 2026; pharmacy fulfillment, updated September 5, 2026; cancellation policy, updated May 18, 2026. Published promises, not a completed checkout or confirmed state-specific fill.
17. Perfect B. BPC-157 cost article, published May 19 and marked updated October 13, 2026, while its body still labels prices as current May 2026; peptide treatment-plan page. The six-cycle price appears in the article, not the inspected plan menu.
18. Robertson Wellness & Aesthetics. BPC-157 product listing and peptide consultation.
19. Rx Peps Direct. Pricing; BPC-157 injection offer; capsule offer; order-price examples; refund policy, updated June 2026; terms, updated March 2026; sample report ETX-260727-0539, testing completed July 31, 2026.

Research and other

20. Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. 2021.
21. Lee E, Burgess K. Intravenous BPC-157 pilot in two adults (PDF). 2025.
22. ClinicalTrials.gov. NCT07803250, NCT07437547, NCT07752381, and NCT02637284. Complete records were read through the official API: Arkansas, hamstring, gummies, oral tablets. No recruitment was independently confirmed.
23. World Anti-Doping Agency. 2026 Prohibited List, effective January 1, 2026. BPC-157 appears under S0 on page 4.
24. Other published rankings reviewed for what they say—not for medical, regulatory, or current provider-offer conclusions: TrimRx, June 12, 2026; Telehealth Ally, marked reviewed April 2026.
25. U.S. Food and Drug Administration. Online-pharmacy checks and state pharmacy-board directory. These are verification resources, not a list of BPC-157 suppliers.